Hubei Guangji Pharmaceutical Co Ltd (SHE:000952) — Market Cap & Net Worth
Market Cap & Net Worth: Hubei Guangji Pharmaceutical Co Ltd (000952)
Hubei Guangji Pharmaceutical Co Ltd (SHE:000952) has a market capitalization of $302.41 Million (CN¥2.07 Billion) as of June 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #14885 globally and #4424 in its home market, demonstrating a -4.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hubei Guangji Pharmaceutical Co Ltd's stock price CN¥5.96 by its total outstanding shares 346750339 (346.75 Million). Review Hubei Guangji Pharmaceutical Co Ltd (000952) financial obligations to assess the company's total debt and financial obligations.
Hubei Guangji Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Hubei Guangji Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $943.64 Million to $302.41 Million (-5.21% CAGR).
Hubei Guangji Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hubei Guangji Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.57x
Hubei Guangji Pharmaceutical Co Ltd's market cap is 0.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $808.25 Million | $714.72 Million | $141.84 Million | 1.13x | 5.70x |
| 2017 | $588.75 Million | $801.56 Million | $105.21 Million | 0.73x | 5.60x |
| 2018 | $410.76 Million | $843.83 Million | $171.73 Million | 0.49x | 2.39x |
| 2019 | $393.82 Million | $731.34 Million | $86.94 Million | 0.54x | 4.53x |
| 2020 | $372.94 Million | $688.17 Million | $74.65 Million | 0.54x | 5.00x |
| 2021 | $394.01 Million | $785.57 Million | $110.11 Million | 0.50x | 3.58x |
| 2022 | $388.67 Million | $797.64 Million | $50.33 Million | 0.49x | 7.72x |
| 2023 | $405.42 Million | $737.82 Million | -$140.25 Million | 0.55x | N/A |
| 2024 | $313.58 Million | $638.80 Million | -$295.29 Million | 0.49x | N/A |
| 2025 | $356.71 Million | $623.97 Million | -$404.49 Million | 0.57x | N/A |
Competitor Companies of 000952 by Market Capitalization
Companies near Hubei Guangji Pharmaceutical Co Ltd in the global market cap rankings as of June 18, 2026.
Key companies related to Hubei Guangji Pharmaceutical Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $936.50 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #26 globally with a market cap of $564.26 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #41 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $936.50 Billion | $1112.00 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #26 | Johnson & Johnson | NYSE:JNJ | $564.26 Billion | $234.20 |
| #41 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $221.23 |
Hubei Guangji Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Hubei Guangji Pharmaceutical Co Ltd's market cap moved from $943.64 Million to $ 302.41 Million, with a yearly change of -5.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥302.41 Million | -15.22% |
| 2025 | CN¥356.71 Million | +13.75% |
| 2024 | CN¥313.58 Million | -22.65% |
| 2023 | CN¥405.42 Million | +4.31% |
| 2022 | CN¥388.67 Million | -1.35% |
| 2021 | CN¥394.01 Million | +5.65% |
| 2020 | CN¥372.94 Million | -5.30% |
| 2019 | CN¥393.82 Million | -4.12% |
| 2018 | CN¥410.76 Million | -30.23% |
| 2017 | CN¥588.75 Million | -27.16% |
| 2016 | CN¥808.25 Million | -14.35% |
| 2015 | CN¥943.64 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Hubei Guangji Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $302.41 Million USD |
| MoneyControl | $302.41 Million USD |
| MarketWatch | $302.41 Million USD |
| marketcap.company | $302.41 Million USD |
| Reuters | $302.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hubei Guangji Pharmaceutical Co Ltd
Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. It also exports its products. The company was founded in 1969 and is based in Wuxue, China.